Upgrade to SI Premium - Free Trial

Allergan (AGN), Editas Medicine (EDIT) Commence Brilliance Phase 1/2 Clinical Trial of AGN-151587 (EDIT-101) for the Treatment of LCA10

July 25, 2019 9:03 AM
Allergan plc (NYSE: AGN) and Editas Medicine, Inc. (NASDAQ: EDIT), today announced the Brilliance Phase 1/2 clinical trial of AGN-151587 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Management Comments

Next Articles